文献速递胸部CT

动态影像组学特征预测非小细胞肺癌新辅助化疗免疫治疗主要病理缓解

Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
PubMed 文献 · Eur Radiol · 2023-09-22

纳入三个中心206例IIA-IIIB期非小细胞肺癌患者,基于基线与术前增强CT的影像组学特征相对净变化构建动态影像组学模型,预测新辅助化疗免疫治疗后的主要病理缓解,其AUC在训练集、测试集和两个外部验证集分别为0.768、0.732、0.833和0.716,优于治疗前影像组学模型和iRECIST标准。

要点

  • 动态影像组学模型预测主要病理缓解的AUC在外部验证集为0.833和0.716。
  • 动态影像组学模型优于治疗前影像组学模型和iRECIST标准。
  • 动态影像组学特征联合iRECIST可进一步提高预测性能。

核心结论

  • 动态影像组学模型在预测II-III期非小细胞肺癌新辅助化疗免疫治疗的主要病理缓解方面,诊断性能优于治疗前影像组学模型和iRECIST标准。

研究设计与样本

  • 多中心研究,纳入三个中心共206例IIA-IIIB期接受新辅助化疗免疫治疗并手术的非小细胞肺癌患者(Database1=164例,随机按0.7:0.3分为训练集和测试集;Database2=21例和Database3=21例作为两个独立外部验证集),获取基线与术前增强CT,计算影像组学特征相对净变化构建动态影像组学模型,并与治疗前影像组学模型及iRECIST标准比较。

诊断标准与关键数值

  • 动态影像组学模型预测主要病理缓解的AUC在训练集、测试集和两个外部验证集分别为0.768、0.732、0.833和0.716;治疗前影像组学模型分别为0.644、0.616、0.475和0.608;iRECIST标准分别为0.624、0.572、0.650和0.466;动态影像组学特征联合iRECIST的混合模型分别为0.777、0.761、0.850和0.670。

临床应用与阅片要点

  • 动态影像组学特征基于基线与术前CT影像组学特征的相对净变化,可作为无创生物标志物辅助识别新辅助化疗免疫治疗的反应,帮助医生制定更合适的治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate if delta-radiomics features have the potential to predict the major pathological response (MPR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients.

METHODS: Two hundred six stage IIA-IIIB NSCLC patients from three institutions (Database1 = 164; Database2 = 21; Database3 = 21) who received neoadjuvant chemoimmunotherapy and surgery were included. Patients in Database1 were randomly assigned to the training dataset and test dataset, with a ratio of 0.7:0.3. Patients in Database2 and Database3 were used as two independent external validation datasets. Contrast-enhanced CT scans were obtained at baseline and before surgery. The delta-radiomics features were defined as the relative net change of radiomics features between baseline and preoperative. The delta-radiomics model and pre-treatment radiomics model were established. The performance of Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) for predicting MPR was also evaluated.

RESULTS: Half of the patients (106/206, 51.5%) showed MPR after neoadjuvant chemoimmunotherapy. For predicting MPR, the delta-radiomics model achieved a satisfying area under the curves (AUCs) values of 0.768, 0.732, 0.833, and 0.716 in the training, test, and two external validation databases, respectively, which showed a superior predictive performance than the pre-treatment radiomics model (0.644, 0.616, 0.475, and 0.608). Compared with iRECIST criteria (0.624, 0.572, 0.650, and 0.466), a mixed model that combines delta-radiomics features and iRECIST had higher AUC values for MPR prediction of 0.777, 0.761, 0.850, and 0.670 in four sets.

CONCLUSION: The delta-radiomics model demonstrated superior diagnostic performance compared to pre-treatment radiomics model and iRECIST criteria in predicting MPR preoperatively in neoadjuvant chemoimmunotherapy for stage II-III NSCLC.

CLINICAL RELEVANCE STATEMENT: Delta-radiomics features based on the relative net change of radiomics features between baseline and preoperative CT scans serve a vital support tool in accurately identifying responses to neoadjuvant chemoimmunotherapy, which can help physicians make more appropriate treatment decisions.

KEY POINTS: • The performances of pre-treatment radiomics model and iRECIST model in predicting major pathological response of neoadjuvant chemoimmunotherapy were unsatisfactory. • The delta-radiomics features based on relative net change of radiomics features between baseline and preoperative CT scans may be used as a noninvasive biomarker for predicting major pathological response of neoadjuvant chemoimmunotherapy. • Combining delta-radiomics features and iRECIST can further improve the predictive performance of responses to neoadjuvant chemoimmunotherapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Han X, Wang M, Zheng Y, et al. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Eur Radiol. 2023. PMID: 37736804. doi:10.1007/s00330-023-10241-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。